水素分子はゲフィチニブ誘発性ナフタレン急性肺傷害の増悪を酸化ストレスおよび炎症の軽減を介して抑制する
Gefitinib, an EGFR tyrosine kinase inhibitor effective against advanced non-small cell lung cancer, carries a risk of inducing severe acute interstitial pneumonia. Using a mouse model combining intraperitoneal naphthalene injection with oral gefitinib administration, this study examined whether hydrogen-rich water could mitigate the resulting lung damage. Ad libitum consumption of hydrogen-rich water reduced body weight loss and significantly improved survival rates. Lung inflammation, bronchoalveolar lavage fluid cytokine levels, and multiple oxidative stress markers—including decreased pulmonary glutathione, elevated plasma malondialdehyde, and increased 4-hydroxy-2-nonenal in airway cells—were all ameliorated by hydrogen-rich water. Critically, hydrogen did not compromise the anti-tumor activity of gefitinib either in cultured lung cancer cells or in tumor-bearing mice, suggesting that hydrogen-rich water may reduce pulmonary adverse effects of gefitinib without diminishing its oncological efficacy.
Hydrogen-rich water restores pulmonary glutathione, reduces plasma malondialdehyde, and suppresses 4-hydroxy-2-nonenal accumulation in airway cells, thereby limiting oxidative damage to the bronchial wall and attenuating inflammatory cytokine release in bronchoalveolar lavage fluid.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/30710119